4DMT reports Q2 2026 results, completes enrollment for second wet AMD Phase 3 trial

4D Molecular Therapeutics (Nasdaq: FDMT) reported on August 13, 2026 that it had completed enrollment for the 4FRONT-2 global Phase 3 trial of 4D-150 in wet age-related macular degeneration in June 2026, with more than 500 patients expected to be randomized and topline data expected in the second half of 2027¹. The company's other pivotal trial, 4FRONT-1, completed enrollment in February 2026 and randomization of 523 patients in March 2026, with topline data expected in the second quarter of 2027¹.

At the American Society of Retina Specialists meeting on July 18, 2026, 4DMT presented 2-year Phase 2b data from the PRISM trial. In the overall cohort, patients showed a 78% reduction in treatment burden, averaging 2.7 supplemental injections compared with a projected 12.0 injections under on-label aflibercept dosed every 8 weeks¹. In the recently diagnosed subgroup, the reduction was 87%, with 1.6 mean supplemental injections versus the same 12.0-injection projection¹. The company said 4D-150 continued to be well tolerated, with no new inflammation cases reported and no drug-related hypotony, endophthalmitis, or vasculitis findings through 2 to more than 4 years of follow-up as of the data cutoff¹.

For diabetic macular edema, 4DMT plans to begin a global Phase 3 trial in the third quarter of 2026, with 2-year data from the SPECTRA trial expected in the fourth quarter of 2026¹. The company also said it secured a credit facility of up to $200 million from Hercules Capital, drawing an initial $20 million at closing¹, and will hold an Investor Day in New York City on October 21, 2026¹.

On finances, 4DMT reported cash, cash equivalents and marketable securities of $430.6 million as of June 30, 2026¹, and said this position, along with expected payments under its collaboration agreement with Otsuka, is expected to fund operations at least into the second half of 2028¹.